{"slug":"tesamorelin-carpal-tunnel","verification":{"valid":true,"entries":1,"head":"e20d80bcac43c8e2b46ee11dd3f34d3431b366bc4af30d2ac8e06df5984d28c5"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.020858,"waste_cost_usd":0,"total_tokens":13980,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.020858,"tokens_total":13980,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:25:59.221Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Carpal tunnel syndrome\n\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\n\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\n\n## Why Tesamorelin might help you\n\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- Tesamorelin → GH axis / visceral fat\n\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpal tunnel mechanics. No additional peptides are in scope here.\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin as a treatment for carpal tunnel syndrome (human tier: absent). Pharmacovigilance data and prescribing information instead document carpal tunnel syndrome as a reported adverse effect.\n\nA 2025 pharmacovigilance study analyzed over 12 million adverse event reports and found tesamorelin associated with significantly elevated reporting of carpal tunnel syndrome (ROR=20.7) (human tier: observational signal). The FDA label for tesamorelin notes fluid retention effects that can include carpal tunnel syndrome, which are often transient or resolve after stopping the drug (human tier: prescribing information).\n\nGrowth hormone therapies in general have long been linked to carpal tunnel symptoms through fluid retention and soft tissue swelling. One 1993 study observed carpal tunnel syndrome during growth hormone treatment in elderly men (human tier: small trial). Excess GH in conditions like acromegaly also produces similar nerve compression.\n\nNo preclinical (rat or other animal) studies specifically examine tesamorelin for carpal tunnel repair or prevention.\n\n## What scientists say\n\nResearchers note that GH secretagogues like tesamorelin raise circulating GH, which promotes renal sodium retention and can lead to edema in confined spaces such as the carpal tunnel (mechanistic tier). The same pathway that reduces visceral fat can produce musculoskeletal side effects including joint pain and nerve compression in susceptible individuals. Scientists emphasize monitoring for these effects rather than therapeutic use in nerve entrapment conditions.\n\n## What people say on Reddit\n\nAnecdotal reports on forums describe onset of carpal tunnel-like symptoms after starting tesamorelin, with some users linking it to dose or fluid retention. One thread discusses dose reduction to manage symptoms while continuing the peptide (anecdotal tier). Users generally frame it as a side effect to watch rather than a benefit.\n\n## What people say on X\n\nPosts on X mention hand numbness or tingling while using tesamorelin or similar GH secretagogues, often attributed to fluid shifts rather than the original condition (anecdotal tier). Discussions focus on management strategies or discontinuation when symptoms appear.\n\n## What we do not know\n\nNo controlled data exist on whether tesamorelin could improve carpal tunnel through fat loss or tissue repair in any subgroup. Long-term effects on nerve health in people with pre-existing compression remain unstudied. Individual responses to GH-related fluid changes vary widely and cannot be predicted from current evidence.\n\n## Safety and limits\n\nTesamorelin carries labeled warnings for fluid retention and related musculoskeletal effects, including carpal tunnel syndrome. People with existing carpal tunnel are advised caution in prescribing information because the drug may worsen symptoms (human tier: label data). Any discussion of repair pathways must be weighed against documented risk of increased pressure in the tunnel. Evidence does not support use for symptom relief or tissue repair in this condition.","claims":[{"id":"c1","text":"Tesamorelin is associated with carpal tunnel syndrome as a reported side effect in pharmacovigilance data.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct signal from large adverse event database relevant to condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FDA label for tesamorelin lists fluid retention effects that can include carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Official prescribing information confirms adverse effect profile.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Growth hormone treatment has been linked to carpal tunnel syndrome in clinical observations.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Historical clinical data on GH class effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human trials evaluate tesamorelin as treatment for carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Absence of positive evidence for repair use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40510111/","title":"Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study","quote":"tesamorelin (ROR=20.7, 95% CI=13.7-31.3)","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"medical","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) Prescribing Information","quote":"It manifests as increased tissue turgor and musculoskeletal discomfort resulting in a variety of adverse reactions (e.g. edema, arthralgia, carpal tunnel syndrome)","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/8287568/","title":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men","quote":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":11274,"tokens_out":2706,"cost":0.0208575,"prev_hash":"genesis","hash":"e20d80bcac43c8e2b46ee11dd3f34d3431b366bc4af30d2ac8e06df5984d28c5"}]}